The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects
Open Access
- 18 September 2002
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 54 (3) , 262-268
- https://doi.org/10.1046/j.1365-2125.2002.01663.x
Abstract
Aims To measure the unbound plasma concentrations of saquinavir (SQV) and indinavir (IDV) and to relate them to the total plasma concentrations in order to establish the unbound percentage of protease inhibitors in vivo during a full dosage interval profile. Methods HIV‐infected subjects (n = 35; median CD4 cell count = 340 × 106 cells l−1, range: 120–825; viral load < 50 copies ml−1 in 22/35) treated with SQV or IDV containing regimens were studied. Plasma drug samples were collected at 0, 2, 4, 8 and 12 h postdose for the twice daily regimens and 0, 1, 2, 4 and 8 h for the three times daily regimens. Ultra‐filtration was used to separate unbound IDV and SQV in plasma and their respective concentrations were measured by a fully validated method using high performance liquid chromatography‐mass spectometry (h.p.l.c.‐MS/MS). Results Based on the ratio AUCunbound/AUCtotal, the median unbound percentage (95% CI for differences) of SQV and IDV from all the samples studied was 1.19% (0.99, 1.58%) and 36.3% (35.1, 44.2%), respectively. No significant difference was seen in the percentage binding of SQV between patients receiving SQV alone (median = 1.49%) or with ritonavir (median = 1.09%; P = 0.141; 95% CI for difference between medians = −0.145, 0.937) over the pharmacokinetic profile. Similarly, no significant difference was seen in the percentage binding of IDV in patients receiving IDV alone (median 35.2%) or with ritonavir (median = 41.3%; P = 0.069; 95% CI for difference between medians = −0.09, 15.4). The unbound concentrations of SQV (P < 0.0001; 95% CI for r 2 = 0.634, 0.815) and IDV (P < 0.0001; 95% CI for r 2 = 0.830, 0.925) remained constant as a proportion of total concentration over the full dosing profile. Conclusions These in vivo data confirm previously published in vitro measurements of SQV and IDV protein binding. The unbound percentage of both protease inhibitors remained constant over the dosing interval.Keywords
This publication has 24 references indexed in Scilit:
- Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV DiseaseAnnals of Internal Medicine, 2001
- The role of therapeutic drug monitoring in treatment of HIV infectionBritish Journal of Clinical Pharmacology, 2001
- Antiretroviral Therapy in AdultsJAMA, 2000
- Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance TherapyJAMA, 2000
- The Effect of Increasing α1‐Acid Glycoprotein Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease InhibitorsThe Journal of Infectious Diseases, 1999
- Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive PatientsClinical Pharmacokinetics, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human ??1 -acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on ??1 -acid glycoproteinPharmacogenetics, 1996
- Relevance of Plasma Protein Binding to Antiviral Activity and Clinical Efficacy of Inhibitors of Human Immunodeficiency Virus ProteaseThe Journal of Infectious Diseases, 1996
- Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1‐acid glycoprotein.British Journal of Clinical Pharmacology, 1993